Trials / Unknown
UnknownNCT01139203
Prophylaxis of Hepatitis B Virus Recurrence After Liver Transplantation
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Shanghai Jiao Tong University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Entecavir demonstrated superior virologic and biochemical benefits over lamivudine and adefovir. The investigators evaluated the effect of entecavir combined Hepatitis B immune globulin (HBIG) with lamivudine or adefovir or both combined HBIG in Chinese liver transplantation patients with Hepatitis B Virus (HBV) related diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lamivudine adefovir entecavir HBIG | lamivudine 100mg orally daily adefovir 10mg orally daily entecavir 0.5mg orally daily HBIG 2000 unit intravenously during the anhepatic phase,and followed 800 unit intramuscularly daily until day 14,then 400 unit intramuscularly twice weekly |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2012-12-01
- First posted
- 2010-06-08
- Last updated
- 2010-06-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01139203. Inclusion in this directory is not an endorsement.